Medical device manufacturers are bracing for the impact of President Trump’s tariffs, which could lead to higher prices for essential devices such as pacemakers, insulin pumps, and hearing aids. Despite efforts to secure exemptions, the industry did not receive special treatment like pharmaceutical companies did.
With around 40% of medical devices being manufactured overseas, particularly in countries like Mexico and Europe, where tariff rates are set at 25% and 20% respectively, the industry is facing significant challenges. Erik Wexler, CEO of Providence, a health system with 51 hospitals, estimates that tariffs could increase costs by $10 million to $25 million annually. This could have a ripple effect on hospitals, insurers, and ultimately patients who rely on these devices for their health.
The complexity of supply chains means that even devices assembled in the U.S. may contain foreign components subject to tariffs. This could lead to price hikes that will be passed on to consumers, putting additional strain on an already burdened healthcare system. Lobbying groups like the American Hospital Association and AdvaMed have been advocating for exemptions for medical devices, especially those facing shortages.
Ash Shehata, leader of KPMG’s U.S. healthcare sector, sees tariffs as a pressure test for the healthcare supply chain. The industry is already under pressure to reduce costs, and additional tariffs will only exacerbate the situation. A survey of 400 supply-chain professionals found that 65% planned to pass on increased costs to customers, indicating that price increases are inevitable across industries, including medical devices.
As hospitals and manufacturers navigate the challenges posed by tariffs, the healthcare supply chain faces a precarious situation. The impact of tariffs on medical devices could lead to higher costs for hospitals and patients, further straining an already overburdened system. With the healthcare supply chain already fragile, the added stress of tariffs could create a national emergency in terms of access to healthcare, particularly for vulnerable populations.
